Breaking News

Financial Report: Pfizer

April 30, 2013

Revenues disappoint, but new products rise

Pfizer

1Q Revenues: $13.5 billion (-9%)
 
1Q Earnings: $2.8 billion (+53%)
 
Comments: Primary Care sales were down 21% to $3.2 billion impacted a 55% drop in Lipitor revenues and loss of exclusivity and near-term expiration of co-promotion agreements for Aricept and Spiriva. These declines were partially offset by Lyrica sales, up 12% to $1.1 billion. Oncology sales were up 31% to $372 million, driven by recent launches Inlyta and Xalkori in several major markets. Specialty Care sales were down 11% to $3.2 billion. Buying patterns for Prevnar 13 hurt revenues. Emerging Markets sales were up 6% to $2.4 billion. Established Product sales were down 15% to $2.4 billion. Consumer Healthcare sales were up 12% to $811 million. R&D Expenses were $1.7 billion, down 3%. Earnings reflect divested interest in Zoetis.
blog comments powered by Disqus
  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision

  • The Impact of Sample Handling  and Processing on the Outcome of Bioanalytical Testing

    The Impact of Sample Handling and Processing on the Outcome of Bioanalytical Testing

    Haiko Pillu, Head Technical Operations, Life Science Services, SGS Belgium NV||September 8, 2016
    Optimizing bioanalytical procedures to get reliable results in clinical studies

  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture